Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
Login My Member Benefits Archives Research Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    ×
  • Subscribe
Enter stock ticker or keyword
×
5 Ways to Beat the Fed (and Crush Inflation)

Email this Article

Send with mail | ahoo instead.
Required Needs to be a valid email
Required Needs to be a valid email
The Small-Cap Stock That Will Upend a $1.2 Trillion Global Industry
https://moneymorning.com/?p=1128391
Required Please enter the correct value.
Twitter
Stocks: IIPR

The Small-Cap Stock That Will Upend a $1.2 Trillion Global Industry

By Stephen Mack, Associate Editor, Money Morning • November 26, 2019

Start the conversation

Comment on This Story Click here to cancel reply.

Or to contact Money Morning Customer Service, click here.

Your email address will not be published. Required fields are marked *

Some HTML is OK

In 2018, global pharmaceutical spending hit an incredible $1.2 trillion. That's roughly the same size as the GDPs of Norway, Israel, and Ireland combined.

And that number will hit $1.5 trillion by 2023, according to the IQVIA Institute for Human Data Science.

But make no mistake: The drug industry is in store for a major disruption.

For that, you can thank the world's only universal drug, as Money Morning Defense and Tech Specialist Michael Robinson calls it.

It's not a technological breakthrough compound developed in a lab. This miracle drug grows right out of the ground.

We're talking, of course, about cannabis.

And while medical cannabis has been legalized for decades in some states, recent discoveries could totally revolutionize the industry...

The Medical Revolution Sweeping the World

Much of the recent news around cannabis in the last few years has been about its recreational use.

In 2018, Canada became the second country in the world (along with Uruguay) to fully legalize recreational cannabis. And in 2019, Illinois became the 11th U.S. state to legalize the plant for recreational use.

By comparison, the medical uses of cannabis seem like old news. It's been legal in Canada for 18 years, and all but three U.S. states allow for medicinal cannabis to some extent.

But we're only just now starting to see the medical potential of cannabis.

And it's enormous...

Cannabis can now be used to treat 172 different medical conditions, including nausea, anxiety, and epilepsy.

It can also be an effective treatment for pain, as Michael Robinson can attest.

Michael spent years relying on ibuprofen, menthol rub, and muscle relaxants to manage chronic pain in his neck and back.

But a switch to cannabis-based treatment has made Michael's life easier and more pain-free than ever.

Despite the benefits, cannabis has still barely scratched the surface of its potential...

Any other substance with the medicinal properties of cannabis would have been hailed as a "miracle drug" as soon as it was discovered. But because of fears propagated largely by the Federal Bureau of Narcotics in the early 20th century, cannabis was associated with criminals and declared illegal instead.

It's taken decades to erase the stigma - and it still hasn't disappeared completely - but the healthcare industry is finally bringing cannabis treatment into mainstream practice.

For investors, that's a potential gold mine.

According to Coherent Market Insights, the global medical cannabis market is growing at a 24.4% compound annual growth rate (CAGR).

That means it's likely to multiply almost six times over between 2017 and 2025, from $3.5 billion to $20 billion.

There is one catch, though...

While medical cannabis has enormous profit potential, it's a lot like investing in biotech firms. There's a lot of risk involved. You might hit the jackpot if your pick develops the next life-saving drug - or the most effective strain of cannabis. But finding those diamonds in the rough can be very difficult.

That's why we're opting for a backend play.

We've got a small-cap stock for you that doesn't grow the cannabis itself, but directly supports the industry as a whole.

That way we get the upside of medical cannabis while avoiding the risk that comes with investing in a single cannabis grower.

Perhaps most importantly, this pick is playing a critical role in making the medical cannabis revolution possible.

The Stability of a Dividend Stock Plus the Growth Potential of a Cannabis Stock

Join the conversation. Click here to jump to comments…

Stephen MackStephen Mack

About the Author

Browse Stephen's articles | View Stephen's research services

Stephen Mack has been writing about economics and finance since 2011. He contributed material for the best-selling books Aftershock and The Aftershock Investor. He lives in Baltimore, Maryland.

… Read full bio

Login
guest
guest
0 Comments
Inline Feedbacks
View all comments
LIVE
Visit Money Morning Live


Latest News

January 19, 2023 • By Money Morning Stock Research Team

These Stocks Could Go To $0

January 9, 2023 • By Money Morning Stock Research Team

The Government Is Pouring $391 Billion Into These Stocks - Buy Now

December 27, 2022 • By Money Morning Staff Reports

6 IPOs in 2023 You Can’t Afford to Miss
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Profit Takeover This Is VWAP Penny Hawk Trading Today Midday Momentum Pump Up the Close
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Night Trader Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Extreme Profit Hunters Profit Revolution Warlock's World Penny Nation Quantum Data Profits Live Trading Alliance Trade The Close Inside Money Trader Expiration Trader Vega Burst Trader Flashpoint Trader Darknet Hyper Momentum Trader

Ā© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell My Info

wpDiscuz